Scinai Immunotherapeutics Ltd. ADR Company Profile
NASDAQ: SCNIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 1.17 -0.85%
Scinai Immunotherapeutics at a glance
Scinai Immunotherapeutics Ltd. ADR (NASDAQ: SCNI) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Jerusalem, Israel. Scinai Immunotherapeutics is led by Mr. Amir Reichman M.B.A., M.Sc. and employs about 45 people. The company's shares have traded publicly since 2015.
At a market capitalization of $1.6 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001611747, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Scinai Immunotherapeutics do?
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.
Business description based on the company's public filings.
Company information
- Legal name
- Scinai Immunotherapeutics Ltd. ADR
- Ticker
- NASDAQ: SCNI
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Amir Reichman M.B.A., M.Sc.
- Employees
- 45
- Headquarters
- Jerusalem BioPark, Jerusalem, Israel
- Phone
- 972 8 930 2529
- Website
- scinai.com
- IPO year
- 2015
- Market cap
- $1.60M
- SEC CIK
- 0001611747
Companies similar to Scinai Immunotherapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CRISCuris Inc. | 0.6712 | -5.38% | $1.63M | vs SCNI |
| HLSQTessera Defense and Homeland Security Inc. | 0.285 | -2.23% | $2.57M | vs SCNI |
| VIVSVivoSim Labs Inc. | 0.1801 | +1.64% | $2.99M | vs SCNI |
| SLXNSilexion Therapeutics Corp | 0.2146 | -8.64% | $3.11M | vs SCNI |
| CLDICalidi Biotherapeutics Inc. | 1.03 | -0.96% | $3.79M | vs SCNI |
| PMCBPharmaCyte Biotech Inc. | 0.4044 | +0.12% | $4.34M | vs SCNI |
| LIMNLiminatus Pharma Inc. Class A | 3.76 | +1.90% | $5.05M | vs SCNI |
| CELZCreative Medical Technology Holdings Inc. | 0.8385 | -2.53% | $6.37M | vs SCNI |